Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction

GlaxoSmithKline Biologicals SA

Division of GlaxoSmithKline PLC
www.gsk.com

Latest From GlaxoSmithKline Biologicals SA

Bookmark
  • News

Finance Watch: Q1 Numbers Suggest A Brisk VC Deal Pace For Cell And Gene Therapies In 2019

By Mandy Jackson

An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.

Financing Regenerative Medicine
Bookmark
  • News

Anticancers, Orphans & The First CAR-Ts: New EU Drug Approvals In 2018

By Ian Schofield

New approvals in the EU were again dominated by oncology drugs in 2018, although medicines for infectious diseases were a close second. The number of orphan drugs more than doubled over the previous year, to 17. There were also some star arrivals in multiple sclerosis, genetic disorders, metabolism and migraine.

Approvals Europe
Bookmark
  • News

EU New Drug Approvals 2018: Anticancers, Orphans, The First CAR-Ts – And More

By Ian Schofield
New drug approvals in the EU were again dominated by oncology in 2018, although medicines for infectious diseases came a close second. The number of orphan drugs more than doubled over the previous year, to 17. There were also some key new arrivals in the areas of multiple sclerosis, genetic disorders, metabolism and migraine.
Approvals Europe
Bookmark
  • News

Biosimilar Litigation: Celltrion, Pfizer Claim Victory On Janssen’s Remaining Infringement Claim

By Sue Sutter

Ensnarement defense bars Remicade maker from prevailing on claim that Inflectra partners infringed cell culture media patent, US federal judge rules.


Biosimilars Intellectual Property
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Belgium
  • Parent & Subsidiaries
  • GlaxoSmithKline PLC
  • Senior Management
  • Jean Stephenne, Chmn. & Pres.
  • Contact Info
  • GlaxoSmithKline Biologicals SA
    Phone: (32) 2 656 81 11
    Rue de L'Institute, 89
    Rixensart, 1330
    Belgium
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By